<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="362385">
  <stage>Registered</stage>
  <submitdate>13/04/2012</submitdate>
  <approvaldate>1/05/2012</approvaldate>
  <actrnumber>ACTRN12612000477820</actrnumber>
  <trial_identification>
    <studytitle>Subcutaneous Frusemide in patients with heart failure</studytitle>
    <scientifictitle>The Use of Continuous Subcutaneous Frusemide in Decompensated Heart Failure: can it achieve a diuresis?</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Decompensated Heart Failure</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Frusemide will be administered subcutaneously through a Safe - T intima cannula continuously via a Niki syringe driver. Hourly Frusemide dose will be determined by the treating Cardiologist ( 10-20mg/hour). Length of intervention will be 48hours.</interventions>
    <comparator>No control - feasibility study</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Net urine volume voided</outcome>
      <timepoint>24 hours</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Urine sodium concentration</outcome>
      <timepoint>24 hours</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Time to first void</outcome>
      <timepoint>Measured from commencement of infusion</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Site reactions</outcome>
      <timepoint>4 hourly until end of treatment period at 48 hours- using Organisational Wide Phlebitis Scale 
(RCN,2005)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>creatinine- serum assay</outcome>
      <timepoint>Daily for 4 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>length of hospital stay, number of days out of hospital</outcome>
      <timepoint>data linkage to medical records to 3 months post discharge</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Decompensated heart failure as meaured by 2 or more of the following - increasing weight, shortness of breath, orthopnoea, paroxysmal nocturnal dyspnoea, pulmonary rales, elevated JVP, peripheral and/or abdominal oedema</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Cardiovascular instability, inotropes, and/or BiPAP, Creatinine &gt;250umol/L</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>Non randomised feasibility study.
Patients will be identified from Cardiology ward.</concealment>
    <sequence>Non randomised</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures>Open, non-randomised, prospective feasiblity study</designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/05/2012</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Auckland City Hospital</primarysponsorname>
    <primarysponsoraddress>Department of Cardiology
Level 3
Auckland City Hospital 
Park Rd Grafton
Auckland1030</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>University of Auckland</sponsorname>
      <sponsoraddress>Associate Professor Robyn Dixon
Director of Postgraduate Studies
School of Nursing
University of Auckland 
Park Rd Grafton
Auckland1030</sponsoraddress>
      <sponsorcountry>New Zealand</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The proposed study is a single centre, prospective, feasibility study measuring the effectiveness of continuous sc Frusemide (CSI-F) in achieving a diuresis in patients with decompensated heart failure.Eligible patients with decompensated heart failure who are admitted to Auckland City Hospital will be treated for the first 24 hours with usual therapy (as per Consultant Cardiologist). After 24 hours of usual care, and after obtaining informed consent, patients will receive Frusemide via a continuous subcutaneous infusion.A Safe-T Intima sc cannula will be inserted with an aseptic technique under the skin by the researcher or patients nurse. The infusion dosage will run as per Consultants medical orders via a Niki T34 syringe driver. The dose of Frusemide will be decided by the Cardiology Consultant responsible for the patients care, and will usually be dose for dose that which would be administered IV. Baseline recordings will be taken such as blood pressure (BP), heart rate (HR), respiratory rate (RR), temperature and weight will be taken prior to infusion.Primary outcome measures will be of net urine volume voided, urine sodium concentration, time to first void, weight, breathlessness and peripheral oedema score.Secondary outcome measures will be serum creatinine, site reactions, length of hospital stay, and number of days out of hospital.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Northern X Regional Ethics Committee</ethicname>
      <ethicaddress>Private Bag 92522
Wellesley Street
Auckland 1141</ethicaddress>
      <ethicapprovaldate>8/03/2012</ethicapprovaldate>
      <hrec>NTX/12/02/001</hrec>
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr James Pemberton</name>
      <address>Cardiologist
Department of Cardiology
Level 3
Auckland City Hospital
Park Rd Grafton
Auckland 1030</address>
      <phone>+64 9 3074949</phone>
      <fax>+64 9 3074950</fax>
      <email>jpemberton@adhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Jane Hannah</name>
      <address>Department of Cardiology
Level 3
Auckland City Hospital
Park Rd Grafton
Auckland 1030</address>
      <phone>+ 64 9 3074949</phone>
      <fax>+64 9 3074950</fax>
      <email>jhannah@adhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Jane Hannah</name>
      <address>Department of Cardiology
Level 3
Auckland City Hospital
Park Rd Grafton
Auckland</address>
      <phone>00649 3074949</phone>
      <fax>00649 3074950</fax>
      <email>jhannah@adhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>